Pentixapharm Holding AG, a clinical-stage biotech company based in Berlin, announced on October 23, 2025, that it will significantly reduce early-stage research and development activities to concentrate resources on its most advanced clinical programs. The decision, jointly resolved by the Managing Board and Supervisory Board, includes a workforce reduction of approximately 50% at Pentixapharm AG, with implementation expected to be completed in the first quarter of 2026. The company anticipates that these adjustments will lower annual operating costs and extend its cash runway through the first quarter of 2027.
The prioritization allows Pentixapharm to invest more effectively in its highest-value development programs, particularly the Phase 3-ready CXCR4 flagship program for the improved diagnosis of treatment-resistant hypertension. This move represents a continuation of the clinical development strategy introduced in May 2025, which emphasizes high-value CXCR4-targeted programs. The CXCR4-based developments also include pioneering therapeutic programs in hematological cancers.
"Our Phase 3-ready PentixaFor CXCR4 program for the diagnosis of treatment-resistant hypertension has made significant progress in recent months and remains a central value driver, showcasing Pentixapharm’s clinical development expertise," said Dr. Dirk Pleimes, CEO and CMO of Pentixapharm AG. "Optimizing our operational costs is an important step to enhance the company’s efficiency and lay a solid foundation for achieving the next clinical milestones."
Pentixapharm is also advancing a next-generation antibody platform targeting CD24, an emerging immune-checkpoint marker over-expressed in multiple hard-to-treat cancers. The company's pipeline is complemented by CXCR4 and CD24 intellectual property protection and a reliable isotope supply chain, positioning it for growth in precision medicine. The organizational adjustments are intended to safeguard long-term value and support sustainable growth, with the company committed to supporting affected employees throughout the transition period.
For more details, view the original release on NewMediaWire.
